Pulmonary Outcomes After Autologous Stem Cell Transplant for Hodgkin Lymphoma

Kimberly Davidow, Nancy Bunin, Samuel Goldfarb, Yimei Li, Jason L. Freedman

Research output: Contribution to journalArticlepeer-review


Autologous hematopoietic stem cell transplant (ASCT) may be curative therapy for pediatric patients with relapsed/refractory Hodgkin lymphoma (HL). Therapy for HL may involve pulmonary toxic modalities. Little information exists regarding pulmonary function in these patients post-ASCT. A retrospective chart review was performed for patients undergoing ASCT from February 2012 to December 2019. Lung disease was defined as a z-score ≤-1.7 in forced expiratory volume in the first second (FEV1), forced vital capacity (FVC), total lung capacity (TLC), or diffusing capacity of lung for carbon monoxide. Descriptive and limited statistical analyses were performed. Twenty-eight patients were included. Median age at diagnosis was 15 (2 to 19) and was 17 (4 to 21) at ASCT. Twenty-three received radiation before ASCT. Fourteen received brentuximab before, and 9 after, transplant. Nineteen met criteria for lung disease post-ASCT. Sixteen had lung disease before ASCT. Longitudinal trends for pulmonary function testing parameters did not reach statistical significance, however, FEV1, FVC, and TLC trended towards worsening immediately post-transplant. There was no statistically significant change in FEV1, FVC, or TLC at 2 years as compared with pretransplant data, suggesting no substantial difference from baseline. Diffusing capacity of lung for carbon monoxide showed statistically significant improvement at the 2 year timepoint (P=0.03). This data reinforces the importance of close follow-up for these patients. Large cohort studies are necessary to identify risk factors so that possible mitigative strategies or alternate regimens could be used.

Original languageEnglish (US)
Pages (from-to)E926-E929
JournalJournal of pediatric hematology/oncology
Issue number6
StatePublished - Aug 1 2022

Bibliographical note

Publisher Copyright:
© 2022 Lippincott Williams and Wilkins. All rights reserved.


  • ASCT
  • Hodgkin lymphoma
  • brentuximab
  • lung disease


Dive into the research topics of 'Pulmonary Outcomes After Autologous Stem Cell Transplant for Hodgkin Lymphoma'. Together they form a unique fingerprint.

Cite this